Myeloid lineage osteoclasts are the sole effective bone-resorbing cells. Osteoclasts are required for the resorptive phase of physiological bone remodeling that maintains musculoskeletal integrity and regulates bone mass. Under physiological conditions the generation and function of osteoclasts is tightly regulated and coupled to the function of bone-forming osteoblast lineage cells. Many pathological conditions associated with excessive bone resorption and bone loss are characterized by loss of normal regulation/coupling, and excessive osteoclastogenesis. The long term goals of this project are to elucidate new mechanisms that suppress osteoclastogenesis, with the associated goal of using this information to develop new therapeutic approaches to suppress pathological bone resorption. Inflammation is an important driver of pathological bone loss. Inflammation decreases bone mass by suppressing osteoblast-mediated bone formation, and concomitantly strongly promoting bone resorption by increasing the differentiation and bone-resorbing function of osteoclasts. Thus, inflammation induces local bone erosion/osteolysis at inflammatory sites in diseases such as rheumatoid arthritis, periodontitis, infections, and orthopedic implant loosening. Recent work, including contributions from our laboratory, has made clear that potent inflammatory factors, such as the inflammatory cytokines IFN-? and GM-CSF and ligands for Toll-like receptors (TLRs) that sense microbial products and tissue damage, also induce feedback inhibition mechanisms that restrain osteoclastogenesis and thus limit the amount of bone resorption that occurs in inflammatory settings. Little is known about feedback inhibitory mechanisms induced by inflammatory factors to limit osteoclastogenesis. Based on our overarching hypothesis that augmenting feedback mechanisms represents an attractive alternative therapeutic approach to suppress pathologic bone resorption, we have investigated mechanisms by which inflammatory signaling restrains osteoclastogenesis. We have discovered two novel and complementary mechanisms by which inflammatory factors, including ligands for Toll like receptors and ITAM-associated receptors, suppress differentiation of osteoclast precursors. These are: 1. Modulation of a proteolytic pathway that generates a biologically active intracellular fragment of the Fms receptor for M-CSF. 2. Induction of the BCL6 transcriptional repressor to inhibit expression of the 'master regulator'of osteoclastogenesis NFATc1. These novel inhibitory mechanisms target two major nonredundant proteins required for osteoclast differentiation, Fms and NFATc1, and effectively inhibit osteoclastogenesis. We will characterize these inhibitory mechanisms to obtain knowledge that can be used to develop new approaches to suppress osteoclastogenesis and pathologic bone resorption by augmenting these mechanisms therapeutically.

Public Health Relevance

Inflammation activates cells called osteoclasts to damage bones in diseases such as rheumatoid arthritis, periodontitis, infections, and orthopedic implant loosening. We have identified and will investigate new molecular mechanisms that inhibit osteoclasts. This work will generate knowledge that can be used to develop new treatments to limit the amount of pathological bone damage that occurs in various musculoskeletal and inflammatory diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute of Dental & Craniofacial Research (NIDCR)
Type
Research Project (R01)
Project #
5R01DE019420-06
Application #
8481532
Study Section
Skeletal Biology Structure and Regeneration Study Section (SBSR)
Program Officer
Lumelsky, Nadya L
Project Start
2008-09-08
Project End
2017-06-30
Budget Start
2013-07-01
Budget End
2014-06-30
Support Year
6
Fiscal Year
2013
Total Cost
$421,200
Indirect Cost
$181,200
Name
Hospital for Special Surgery
Department
Type
DUNS #
622146454
City
New York
State
NY
Country
United States
Zip Code
10021
Park-Min, Kyung-Hyun; Lim, Elisha; Lee, Min Joon et al. (2014) Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Nat Commun 5:5418
Ivashkiv, Lionel B; Donlin, Laura T (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36-49
Park-Min, Kyung-Hyun; Lee, Eun Young; Moskowitz, Neal K et al. (2013) Negative regulation of osteoclast precursor differentiation by CD11b and *2 integrin-B-cell lymphoma 6 signaling. J Bone Miner Res 28:135-49
Ivashkiv, Lionel B (2013) Epigenetic regulation of macrophage polarization and function. Trends Immunol 34:216-23
Yarilina, Anna; Xu, Kai; Chen, Janice et al. (2011) TNF activates calcium-nuclear factor of activated T cells (NFAT)c1 signaling pathways in human macrophages. Proc Natl Acad Sci U S A 108:1573-8
Ivashkiv, Lionel B; Zhao, Baohong; Park-Min, Kyung-Hyun et al. (2011) Feedback inhibition of osteoclastogenesis during inflammation by IL-10, M-CSF receptor shedding, and induction of IRF8. Ann N Y Acad Sci 1237:88-94
Park, Sung Ho; Park-Min, Kyung-Hyun; Chen, Janice et al. (2011) Tumor necrosis factor induces GSK3 kinase-mediated cross-tolerance to endotoxin in macrophages. Nat Immunol 12:607-15
James, Douglas E; Nestor, Bryan J; Sculco, Thomas P et al. (2010) The relative timing of exposure to phagocytosable particulates and to osteoclastogenic cytokines is critically important in the determination of myeloid cell fate. J Immunol 185:1265-73
Kalliolias, George D; Zhao, Baohong; Triantafyllopoulou, Antigoni et al. (2010) Interleukin-27 inhibits human osteoclastogenesis by abrogating RANKL-mediated induction of nuclear factor of activated T cells c1 and suppressing proximal RANK signaling. Arthritis Rheum 62:402-13
Lee, Bitnara; Kim, Tae-Hwan; Jun, Jae-Bum et al. (2010) Direct inhibition of human RANK+ osteoclast precursors identifies a homeostatic function of IL-1beta. J Immunol 185:5926-34

Showing the most recent 10 out of 15 publications